{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T01:43:58Z","timestamp":1782524638267,"version":"3.54.5"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We aimed to assess patient exposure to isavuconazole (ISZ) from samples received in our laboratory for therapeutic antifungal monitoring. We used liquid chromatography coupled with ultraviolet (UV) absorbance detection adapted from a multiplex-validated method with photodiode array (PDA) detection to monitor the analytes. The latter device allows the characterization of the azoles UV spectra. The method was validated according to international guidelines for efficient ISZ monitoring.<\/jats:p>\n               <jats:p>The assay exhibited linearity between 0.25 and 16\u00a0mg\/l for ISZ. Accuracy and intra- and inter-day precision were within acceptable ranges, and the method was successfully applied to quantify azoles and major metabolites from clinical samples collected from treated patients. We focus on ISZ blood concentrations and compared them to those of voriconazole, posaconazole, and itraconazole for a period of 5 years (2017\u20132021). Median ISZ concentration was 2.92\u00a0mg\/l (interquartile range 1.82\u20135.33\u00a0mg\/l) with 89% of measurements classified as adequate exposure (&amp;gt; 1\u00a0mg\/l). Additionally, 71% of samples reach concentration values &amp;gt; 2\u00a0mg\/l. Different ISZ exposure between adults to children were found.<\/jats:p>\n               <jats:p>In conclusion, ISZ achieves excellent blood concentrations compared to other azole drugs, they are almost identical to those previously described, they exceed the MICs of most fungi for which its use was recommended and they differ depending on the patient\u2019s age. The method we describe for antifungal monitoring is simple, robust, and efficient. It simultaneously analyzes azoles and metabolites, and can be used for tailored interventions, achieve exposures associated with therapeutic success, decrease treatment-related toxicity, and help prevent resistance emergence due to continuous azole sub-optimal concentrations.<\/jats:p>","DOI":"10.1093\/mmy\/myad086","type":"journal-article","created":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T04:06:45Z","timestamp":1691899605000},"source":"Crossref","is-referenced-by-count":8,"title":["Observed isavuconazole exposure: 5-year experience of azole TDM from a Spanish reference laboratory"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2780-5039","authenticated-orcid":false,"given":"Alicia","family":"Gomez-Lopez","sequence":"first","affiliation":[{"name":"Mycology Reference and Research Laboratory (National Centre for Microbiology CNM-ISCIII) , Instituto de Salud Carlos III Carretera Majadahonda-Pozuelo Km 2 28220 Madrid , Spain"},{"name":"Center for Biomedical Research in Network in Infectious Diseases (CIBERINFEC-CB21\/13\/00105) , Instituto de Salud Carlos III. Carretera Majadahonda-Pozuelo Km 2 Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Sanchez\u00a0Galiano","sequence":"additional","affiliation":[{"name":"Mycology Reference and Research Laboratory (National Centre for Microbiology CNM-ISCIII) , Instituto de Salud Carlos III Carretera Majadahonda-Pozuelo Km 2 28220 Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Ortega\u00a0Madue\u00f1o","sequence":"additional","affiliation":[{"name":"Mycology Reference and Research Laboratory (National Centre for Microbiology CNM-ISCIII) , Instituto de Salud Carlos III Carretera Majadahonda-Pozuelo Km 2 28220 Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Carballo\u00a0Gonzalez","sequence":"additional","affiliation":[{"name":"Mycology Reference and Research Laboratory (National Centre for Microbiology CNM-ISCIII) , Instituto de Salud Carlos III Carretera Majadahonda-Pozuelo Km 2 28220 Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"key":"2023082519422423000_bib1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13696998.2019.1638789","article-title":"The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom","volume":"23","author":"Floros","year":"2020","journal-title":"J Med Econ"},{"key":"2023082519422423000_bib2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24 Suppl 1","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2023082519422423000_bib3","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40265-022-01751-x","article-title":"Global consumption trend of antifungal agents in humans from 2008 to 2018: Data from 65 middle- and high-income countries","volume":"82","author":"Pathadka","year":"2022","journal-title":"Drugs"},{"key":"2023082519422423000_bib4","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1016\/j.cmi.2016.01.017","article-title":"EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents","volume":"22","author":"Arendrup","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2023082519422423000_bib5","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2023082519422423000_bib6","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: A systematic review and meta-analysis","volume":"71","author":"Jin","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023082519422423000_bib7","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: A meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023082519422423000_bib8","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: A position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"2023082519422423000_bib9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diagmicrobio.2018.04.003","article-title":"Simultaneous quantification of systemic azoles and their major metabolites in human serum by HPLC\/PDA: Role of azole metabolic rate","volume":"92","author":"Gomez-Lopez","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023082519422423000_bib10","article-title":"Use CfMPfH ICH guideline M10 on bioanalytical method validation and study sample analysis","author":"Agency EM","year":"2022"},{"key":"2023082519422423000_bib11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/FTD.0000000000000952","article-title":"Antifungal drugs TDM: Trends and update","volume":"44","author":"Kably","year":"2022","journal-title":"Ther Drug Monit"},{"key":"2023082519422423000_bib12","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023082519422423000_bib13","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023082519422423000_bib14","doi-asserted-by":"crossref","first-page":"e00585","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: Consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023082519422423000_bib15","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/mmy\/myaa022","article-title":"Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center","volume":"58","author":"Borman","year":"2020","journal-title":"Med Mycol"},{"key":"2023082519422423000_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/jof6020090","article-title":"Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: Outcome, tolerability and clinical implications of Isavuconazole plasma concentrations","volume":"6","author":"Zurl","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2023082519422423000_bib17","doi-asserted-by":"crossref","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","article-title":"New perspectives on antimicrobial agents: Isavuconazole","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob Agents Chemother."},{"key":"2023082519422423000_bib18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3390\/jof8040362","article-title":"Experience of Isavuconazole as a salvage therapy in chronic pulmonary fungal disease","volume":"8","author":"Nwankwo","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2023082519422423000_bib19","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/cid\/ciac230","article-title":"Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies","volume":"75","author":"Rausch","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023082519422423000_bib20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/jof7050376","article-title":"Penetration of isavuconazole in ascites fluid of critically ill patients","volume":"7","author":"Lahmer","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2023082519422423000_bib21","doi-asserted-by":"crossref","first-page":"e00524","DOI":"10.1128\/AAC.00524-19","article-title":"Tissue distribution and penetration of isavuconazole at the site of infection in experimental invasive aspergillosis in mice with underlying chronic granulomatous disease","volume":"63","author":"Lee","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023082519422423000_bib22","doi-asserted-by":"crossref","first-page":"e02474","DOI":"10.1128\/AAC.02474-18","article-title":"Isavuconazole diffusion in infected human brain","volume":"63","author":"Rouzaud","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2023082519422423000_bib23","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1093\/mmy\/myy067","article-title":"Beyond tissue concentrations: Antifungal penetration at the site of infection","volume":"57","author":"Zhao","year":"2019","journal-title":"Med Mycol"},{"key":"2023082519422423000_bib24","doi-asserted-by":"crossref","first-page":"e01643","DOI":"10.1128\/AAC.01643-18","article-title":"Pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients","volume":"62","author":"Wu","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023082519422423000_bib25","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: Focus on drugs without a clear recommendation","volume":"26","author":"Gomez-Lopez","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2023082519422423000_bib26","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/myc.12910","article-title":"Real-world use-isavuconazole at a large academic medical center","volume":"62","author":"Hassouna","year":"2019","journal-title":"Mycoses"},{"key":"2023082519422423000_bib27","doi-asserted-by":"crossref","first-page":"e0212837","DOI":"10.1371\/journal.pone.0212837","article-title":"A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia","volume":"14","author":"Arrieta","year":"2019","journal-title":"PLoS One"},{"key":"2023082519422423000_bib28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/03602532.2019.1632888","article-title":"Novel insights into the complex pharmacokinetics of voriconazole: A review of its metabolism","volume":"51","author":"Schulz","year":"2019","journal-title":"Drug Metab Rev"},{"key":"2023082519422423000_bib29","doi-asserted-by":"crossref","first-page":"e0029021","DOI":"10.1128\/AAC.00290-21","article-title":"Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients","volume":"65","author":"Arrieta","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023082519422423000_bib30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40272-020-00379-2","article-title":"Administration and dosing of systemic antifungal agents in pediatric patients","volume":"22","author":"Downes","year":"2020","journal-title":"Paediatr Drugs"},{"key":"2023082519422423000_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40262-019-00735-7","article-title":"Voriconazole: A review of population pharmacokinetic analyses","volume":"58","author":"Shi","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2023082519422423000_bib32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole","volume":"80","author":"Chen","year":"2020","journal-title":"Drugs"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myad086\/51112194\/myad086.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/61\/8\/myad086\/51261413\/myad086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/61\/8\/myad086\/51261413\/myad086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T19:42:41Z","timestamp":1692992561000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myad086\/7242555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myad086","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,8]]},"article-number":"myad086"}}